Pharmaceutical Business Development

Transcription

1 Pharmaceutical Business Development Investor Day - June 13, 2012 NASDAQ:CBLI

2 Safe Harbor This presentation includes forward-looking statements and predictions, including statements about potential revenue-bearing transactions, the market potential of CBLI s technologies and product candidates, and the potential value of pipeline products. These statements represent CBLI s judgment as of the date of this presentation and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. In particular, CBLI faces risks and uncertainties that it may not be able to sustain its business model, that revenues may be lower or expenses higher than projected, that product sales may not increase, that development of product candidates in the Company s pipeline may not succeed or that commercial transactions may not go forward as planned. The factors that could cause actual results to differ are discussed in more detail in CBLI s filings with the Securities and Exchange Commission, including its latest Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These reports are available under the Investors tab on CBLI s website at 2

3 Business Development Deborah Bowes, M.T., VP Business Development 3

4 Biography 30 years in Biotech/Pharmaceuticals Hybritech/Lilly Centocor/J&J Agouron/Pfizer Amylin MedImmune/AZ Founded Biotech Consulting Practice focused on licensing and strategic planning Expertise in Licensing/Business Development (5 major product deals) Corporate and Product Strategic Planning (managed and built 2 dept.s) Launched & Marketed 4 Biotech products (2 Oncology) 4

5 Biography (cont.) Science background Extensive network and relationships with Heads of BD at 1 st and 2 nd tier pharma companies Worked on the buy and sell side of pharma licensing Understand processes in both small start-ups and big pharma Oncology and biologics is my sweet-spot Covered all major therapeutic areas in 30-year career (including orphan) 5

6 Deal Benchmarks for Oncology Oncology deals represented 24% of all pharma transactions in 2011 Phase of License # of Licenses Median Upfront Milestone Median Total Deal Value Research 12 $12M $320M 54% IND 7 $22M $450M Phase I/II 10 $56M $580M Phase III 6 $123M $1,100M 6

7 Oncology Drug Pricing Benchmarks Direct effect on product value Category of Indication Treatment Effect Pricing Benchmark Range Cancer Therapy Directly effects tumor growth and progression $70-140K/patient Cancer Supportive Care Mitigates side effects of cancer therapy $5-30K/patient Orphan Indication Indications with less than 200K prevalence $30-400K/patient 7

8 CBLI s Oncology/Orphan Product Pipeline Product Research Pre-clinical Ph I Ph II Ph III CBLB502 Healthy Subject Safety Study Advanced Solid Tumor Head & Neck CBL0137 Advanced Solid Tumors (oral) Advanced Solid Tumor (IV) CBLB612 Bone Marrow Transplantation HSC enrichment* *HSC: hematopoietic stem cell 8

9 CBLI s Oncology/Orphan Pipeline Product Positioning to Optimize Value Product Positioning CBLB502 Cancer Therapy Novel Biologic Targeted Therapy with Companion Diagnostic CBL0137 Cancer Therapy Novel Small Molecule Novel Chemotherapy CBLB612 Orphan drug Novel Biologic 9

10 Q&A 10